Dare Bioscience announced it will receive a payment of $1 million as the latest installment under a grant agreement to advance the development of Dare‘s investigational contraceptive DARE-LARC1 through nonclinical proof of principle studies and other IND-enabling work to allow for the submission of an Investigational New Drug, IND, Application with the FDA, approval of which will be required to commence testing in humans. Under the terms of the grant agreement, Dare may receive a total of up to approximately $49 million to support nonclinical development of DARE-LARC1. To date, Dare has received payments totaling approximately $28.3 million. Additional payments are conditioned on the program meeting specified development and reporting milestones.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DARE:
- Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1
- Biotech Alert: Searches spiking for these stocks today
- Dare Bioscience downgraded to Hold from Buy at Brookline
- Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal Contraceptive
- Dare Bioscience announces publication of data from Ovaprene study